BeiGene Ltd. ADR (BGNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
BGNE POWR Grades
- BGNE scores best on the Growth dimension, with a Growth rank ahead of 96.4% of US stocks.
- BGNE's strongest trending metric is Growth; it's been moving up over the last 179 days.
- BGNE's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).
BGNE Stock Summary
- With a market capitalization of $18,632,228,066, BEIGENE LTD has a greater market value than 89.4% of US stocks.
- BGNE's price/sales ratio is 14.91; that's higher than the P/S ratio of 92.73% of US stocks.
- BEIGENE LTD's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -18.66%, greater than the shareholder yield of only 20.76% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to BEIGENE LTD, a group of peers worth examining would be SGEN, LXRX, PXLW, FBIO, and QRVO.
- Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Valuation Summary
- In comparison to the median Healthcare stock, BGNE's price/sales ratio is 625% higher, now standing at 14.5.
- Over the past 83 months, BGNE's price/sales ratio has gone down 51.6.
Below are key valuation metrics over time for BGNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BGNE | 2022-11-25 | 14.5 | 3.9 | -8.5 | -6.8 |
| BGNE | 2022-11-23 | 15.1 | 4.1 | -8.8 | -7.2 |
| BGNE | 2022-11-22 | 14.7 | 3.9 | -8.5 | -6.9 |
| BGNE | 2022-11-21 | 16.2 | 4.3 | -9.4 | -7.8 |
| BGNE | 2022-11-18 | 16.9 | 4.5 | -9.8 | -8.2 |
| BGNE | 2022-11-17 | 16.7 | 4.5 | -9.7 | -8.1 |
BGNE Growth Metrics
- The 4 year net income to common stockholders growth rate now stands at -860.2%.
- Its 4 year revenue growth rate is now at 37511.03%.
- Its year over year net income to common stockholders growth rate is now at -64.07%.
The table below shows BGNE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1,249.805 | -1,686.267 | -2,148.932 |
| 2022-06-30 | 1,068.617 | -1,620.074 | -2,005.231 |
| 2022-03-31 | 877.037 | -1,660.381 | -1,914.123 |
| 2021-12-31 | 1,176.283 | -1,298.723 | -1,413.354 |
| 2021-09-30 | 1,062.404 | -1,123.218 | -1,300.446 |
| 2021-06-30 | 947.044 | -973.746 | -1,311.815 |
BGNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
- BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
- AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.
The table below shows BGNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.168 | 0.883 | -0.377 |
| 2021-03-31 | 0.165 | 0.897 | -0.358 |
| 2020-12-31 | 0.065 | 0.771 | -0.552 |
| 2020-09-30 | 0.070 | 0.746 | -0.678 |
| 2020-06-30 | 0.078 | 0.704 | -0.890 |
| 2020-03-31 | 0.166 | 0.826 | -0.893 |
BGNE Stock Price Chart Interactive Chart >
BGNE Price/Volume Stats
| Current price | $194.57 | 52-week high | $365.16 |
| Prev. close | $191.61 | 52-week low | $118.18 |
| Day low | $188.32 | Volume | 284,700 |
| Day high | $197.84 | Avg. volume | 283,458 |
| 50-day MA | $166.97 | Dividend yield | N/A |
| 200-day MA | $170.25 | Market Cap | 20.20B |
BeiGene Ltd. ADR (BGNE) Company Bio
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
In the wake of BeiGene, Ltd.'s (NASDAQ:BGNE) latest US$2.9b market cap drop, institutional owners may be forced to take severe actionsEvery investor in BeiGene, Ltd. ( NASDAQ:BGNE ) should be aware of the most powerful shareholder groups. The group... |
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH22--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in pati |
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) |
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, November 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA® (ibrutinib) in pat |
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL. “This approval represents an important milestone for CLL patients and their physicians who now have a new chemotherapy-free treatment option, and an alternative to cur |
BGNE Price Returns
| 1-mo | 9.05% |
| 3-mo | 16.59% |
| 6-mo | 37.11% |
| 1-year | -43.74% |
| 3-year | -2.67% |
| 5-year | 140.21% |
| YTD | -28.18% |
| 2021 | 4.85% |
| 2020 | 55.88% |
| 2019 | 18.18% |
| 2018 | 43.53% |
| 2017 | 221.87% |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...